The Democratic Republic of Congo begins new vaccine trials aimed at preventing the Bundibugyo Ebola strain as the current outbreak continues to kill thousands. Premium Times reports the trial has started and is named “Tumaini” (“hope” in Swahili), with the goal of testing vaccine candidates for a virus strain that currently has no approved vaccine.
Forbes similarly reports that Ebola vaccine trials are underway in the DRC, describing them as late-stage and linked to efforts to address what it frames as the country’s most deadly Ebola outbreak. While both outlets focus on the start of the trials and the Bundibugyo strain, they differ slightly in emphasis: Premium Times highlights the trial name and the absence of an approved vaccine, while Forbes foregrounds the trial stage and the proximity of the death toll to roughly 4,700.
Both reports place the vaccine testing within the broader context of an ongoing, high-fatality outbreak in the DRC, with no single vaccine already approved for this strain.
